Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF<sup>V600E</sup>-Mutated Anaplastic Thyroid Carcinoma-Reference-Cited by-同舟云学术

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF^V600E-Mutated Anaplastic Thyroid Carcinoma

Published:2024-03-01 Issue:3 Volume:34 Page:336-346
ISSN:1050-7256
Container-title:Thyroid®
language:en
Short-container-title:Thyroid®

Author:

Hamidi Sarah¹^ORCID,Iyer Priyanka C.¹,Dadu Ramona¹,Gule-Monroe Maria K.²,Maniakas Anastasios³^ORCID,Zafereo Mark E.³^ORCID,Wang Jennifer R.³^ORCID,Busaidy Naifa L.¹,Cabanillas Maria E.¹

Affiliation:

1. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

2. Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

3. Department of Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2023.0573

Reference39 articles.

1. Recent incidences and differential trends of thyroid cancer in the USA

2. New hope for patients with BRAF V600E-mutant anaplastic thyroid cancer: lights and shadows

3. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

4. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer

5. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anaplastic thyroid cancer: A review of recent evidence and summary of an Australian institutional protocol;Asia-Pacific Journal of Clinical Oncology;2024-08-15

2. Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer;Expert Opinion on Pharmacotherapy;2024-08-12

3. Therapeutic treatments targeting communication between angiogenic and immune microenvironments in thyroid cancers;Current Opinion in Endocrine and Metabolic Research;2024-08

4. PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma;American Journal of Surgical Pathology;2024-07-15

5. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer;JAMA Oncology;2024-07-11